OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer

September 27th, 2018|0 Comments

BATON ROUGE, La., Sept. 27, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov

July 9th, 2018|0 Comments

BATON ROUGE, La., July 09, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients

June 20th, 2018|0 Comments

BATON ROUGE, La., June 20, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial

March 28th, 2018|0 Comments

BATON ROUGE, La., March 28, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial

March 22nd, 2018|0 Comments

BATON ROUGE, La., March 22, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Announces Presentation at the 2018 AACR Annual Meeting

March 20th, 2018|0 Comments

BATON ROUGE, La., March 20, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Appoints Robert Neal Holcomb to Board of Directors

March 19th, 2018|0 Comments

BATON ROUGE, La., March 19, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

March 8th, 2018|0 Comments

BATON ROUGE, La., March 08, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas

February 28th, 2018|0 Comments

BATON ROUGE, La., Feb. 28, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Provides Updates on Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

February 26th, 2018|0 Comments

BATON ROUGE, La., Feb. 26, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas

February 5th, 2018|0 Comments

BATON ROUGE, La., Feb. 05, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time

January 10th, 2018|0 Comments

BATON ROUGE, La., January 10, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

December 21st, 2017|0 Comments

100% Overall Survival Rate in 14 Evaluable Patients at One-Year Follow-Up BATON ROUGE, La., Dec. 21, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a [...]

100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

December 5th, 2017|0 Comments

BATON ROUGE, La., Dec. 05, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy [...]

80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

November 13th, 2017|0 Comments

BATON ROUGE, La., Nov. 13, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine

October 17th, 2017|0 Comments

BATON ROUGE, La., Oct. 17, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia

September 29th, 2017|0 Comments

BATON ROUGE, La., Sept. 29, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer

September 14th, 2017|0 Comments

BATON ROUGE, LA, Sept. 14, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]

OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment

August 31st, 2017|0 Comments

BATON ROUGE, LA--(August 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a [...]

OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference

August 29th, 2017|0 Comments

BATON ROUGE, LA--(August 29, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]